SCNXNasdaq said: not today
Scienture Holdings got a fresh 180-calendar-day extension from Nasdaq after asking for more time to get its closing bid price back above $1. That means the stock can keep trading on the Nasdaq Capital Market for now, even though it’s still in the danger zone.
The catch: the price problem isn’t gone
This isn’t a victory lap so much as a timeout. Nasdaq’s decision only buys Scienture more runway to fix the bid-price issue, and the company already said it may need to use a reverse stock split if the market doesn’t play ball.
Why investors should care
For small-cap pharma names, listing compliance issues can be a nasty distraction. A reverse split can help with the price requirement, but it doesn’t magically improve the business — it just changes the optics and keeps the listing from wobbling off a cliff.
Big picture: Scienture still has a seat at the Nasdaq table, but it’s the kind of seat where you keep checking the exit signs.